lobbying_activities: 1445164
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1445164 | 3b3d64e7-7e64-40cc-afcd-e78794345f22 | Q3 | KNIGHT CAPITOL CONSULTANTS | 40036301 | GENZYME CORPORATION | 2013 | third_quarter | TAX | Possible changes in the tax code that affect the pharmaceutical industry, including the R&D tax credit and the Orphan Drug tax credit. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2013-10-16T19:33:34.300000-04:00 |